-
Incorporation of DNA methylation profiling into the cytopathology laboratory Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-16 Gloria H. Sura, Leomar Y. Ballester
CONFLICT OF INTEREST STATEMENT The authors declared no conflicts of interest.
-
Improving diagnostic yield of pancreatic serous cystadenoma with cyst fluid ancillary testing, adjunct immunohistochemistry, and additional fine‐needle biopsy sampling Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07 Xi Wang, Xuchen Zhang, Pei Hui, Guoping Cai
BackgroundFine‐needle aspiration (FNA) diagnosis of pancreatic serous cystadenoma (SCA) remains challenging. This retrospective study aimed to evaluate the roles of cyst fluid ancillary testing and combined fine‐needle biopsy (FNB) in improving the diagnostic yield.MethodsThe authors retrospectively reviewed cytology cases that were histologically confirmed SCAs. Clinical features and FNA cyst fluid
-
Interobserver agreement in the interpretation of anal cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07 Maria Benevolo, Francesca Rollo, Alessandra Latini, Massimo Giuliani, Amalia Giglio, Eugenia Giuliani, Maria Gabriella Donà
BackgroundAnal cytology represents a tool for anal cancer screening in high‐risk populations. In addition to accuracy, the reproducibility of the interpretation is of key importance. The authors evaluated the agreement of anal cytologic interpretation between two cytopathologists.MethodsLiquid‐based cytologic slides from human immunodeficiency virus (HIV)‐negative men who have sex with men (MSM) were
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07
No abstract is available for this article.
-
Growing threats of a mass exodus in governmental public health Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-07 Bryn Nelson, William Faquin
The backbone of the nation’s public health workforce is buckling. A recent study has raised alarms with its dire prediction of a mass exodus of governmental public health workers—considered the “backbone” of public health efforts in the United States—if current trends hold.1 “In our analytic sample, nearly half of all employees in state and local public health agencies left between 2017 and 2021, a
-
Leveraging archival cerebrospinal fluid samples for genetic insights from cell‐free DNA Cancer Cytopathol. (IF 3.4) Pub Date : 2024-03-01 Alexandra M. Miller, Tejus A. Bale
Cerebrospinal fluid (CSF) samples are often a rich source of tumor‐derived cell‐free DNA (cfDNA), a high degree of success in detecting tumor mutations can even be achieved with archival CSF samples.
-
Interobserver agreement and risk of malignancy using the International Academy of Cytology Yokohama System for reporting breast FNA biopsy in a liquid‐based exclusive cohort Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-27 Olawunmi Folarin, David Kim, Hamza N. Gokozan, Jonas J. Heymann, Jose V. Scarpa Carniello, Lucelina Rosado, Momin T. Siddiqui, Ami Patel
BackgroundPer the College of American Pathologist’s National Breast Fine Needle Aspiration Biopsy (FNAB) Practice Survey, ∼40% of laboratories use liquid‐based cytology (LBC) for breast FNAB. The reproducibility of the International Academy of Cytology Yokohama System (YS) for reporting breast FNAB on LBC was explored.DesignBreast FNAB specimens submitted as LBC only (all ThinPrep) between January
-
Detection of effusion tumor cells under different storage and processing conditions Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-19 Diane M. Libert, Yili Zhu, Aihui Wang, Grace M. Allard, Alarice Cheng‐Yi Lowe
BackgroundCirculating tumor cells (CTCs) shed into blood provide prognostic and/or predictive information. Previously, the authors established an assay to detect carcinoma cells from pleural fluid, termed effusion tumor cells (ETCs), by employing an immunofluorescence‐based CTC‐identification platform (RareCyte) on air‐dried unstained ThinPrep (TP) slides. To facilitate clinical integration, they evaluated
-
Retrospective analysis of cytology and high‐risk HPV testing in 1067 endocervical adenocarcinomas and precursor lesions Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-19 Lei Ye, Meifu Gan, Yeli Yao, Bingjian Lu
BackgroundCytology and high‐risk human papilloma virus (hrHPV) cotesting is the mainstay in the detection of cervical carcinoma.MethodsEndocervical adenocarcinoma (EAC) is divided into HPV‐associated adenocarcinoma (HPVA) and HPV‐independent adenocarcinoma (HPVI) by the World Health Organization classification (2020). The detection effect of cotesting is suggested to be different among EAC subtypes
-
Rapid on-site evaluation of touch imprint cytology in navigation bronchoscopy for small peripheral pulmonary nodules Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-12 Stephan E. P. Kops, Lizanne J. W. van der Burgt, Shoko Vos, Lia J. M. van Zuijlen-Manders, Roel L. J. Verhoeven, Erik H. F. M. van der Heijden
Rapid on-site evaluation (ROSE) of cytopathology plays an important role in determining whether representative samples have been taken during navigation bronchoscopy. With touch imprint cytology (TIC), histologic samples can be assessed using ROSE. Although advised by guidelines, there have been almost no studies on the performance of TIC during navigation bronchoscopy. The objective of this study
-
Prediction of lymph node status in patients with surgically treated head and neck squamous cell carcinoma via neck lavage cytology: A pilot study Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-08 Hugo Rimbach, Maximilian Linxweiler, Sandrina Körner, Sigrun Smola, Barbara Linxweiler, Stefanie Speicher, Johanna Helfrich, Erich-Franz Solomayer, Mathias Wagner, Bernhard Schick, Jan Philipp Kühn
Neck dissection is a standardized surgical procedure for patients with head and neck squamous cell carcinoma (HNSCC) and plays a critical role in the choice of adjuvant treatment based on histopathological findings. Saline irrigation is routinely performed at the end of surgery. However, this irrigant is not used for diagnostic purposes.
-
Urine cytology in the detection of renal cell carcinomas – a territory-wide multi-institutional retrospective review of more than 2 decades Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-08 Joshua J. X. Li, Joanna K. M. Ng, Cheuk-Yin Tang, Bryan C. H. Chan, Sau Yee Chan, Jasmine H. N. Law, Jeremy Y. Teoh, Christopher J. VandenBussche, Gary M. Tse
Compared with urothelial lesions of the upper urinary tract, the diagnostic performance of urine cytology in detection of renal cell carcinomas is underreported. This study aims to establish the role of urine cytology in the assessment of renal carcinomas by a multi-institute review of urine cytology from nephrectomy confirmed renal cell carcinomas, referenced against renal urothelial and squamous
-
Cell block practices in European cytopathology laboratories Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-07 Irena Srebotnik Kirbis, Ivana Kholova, Heini Huhtala, Massimo Bongiovanni, Margareta Strojan Flezar, Chantell Hodgson, Beatrix Cochand-Priollet
There are numerous methods and procedures described for the preparation of cell blocks (CBs) from cytological samples. The objective of this study was to determine current practices and issues with CBs in European laboratories.
-
Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-06 Samantha Peiling Yang, Min En Nga, Manish Mahadeorao Bundele, Simion I. Chiosea, Sze Hwa Tan, Jeffrey H. Y. Lum, Rajeev Parameswaran, Ming Yann Lim, Hao Li, Wei Keat Cheah, Kathleen Su-Yen Sek, Andre Teck Huat Tan, Thomas Kwok Seng Loh, Kee Yuan Ngiam, Wee Boon Tan, Xinyong Huang, Thomas Wai Thong Ho, Keng Hua Lim, Chwee Ming Lim, Reyaz M. Singaporewalla, Anil Dinkar Rao, Nandini C. L. Rao, Dennis
Most thyroid nodules are benign. It is important to determine the likelihood of malignancy in such nodules to avoid unnecessary surgery. The primary objective of this study was to characterize the genetic landscape and the performance of a multigene genomic classifier in fine-needle aspiration (FNA) biopsies of cytologically indeterminate thyroid nodules in a Southeast Asian cohort. The secondary objective
-
Diagnosing medullary thyroid carcinoma is facilitated by measuring calcitonin in FNA washout fluids: Alea iacta est Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-07 Pierpaolo Trimboli, Anna Crescenzi
The prognosis for patients diagnosed with medullary thyroid carcinoma (MTC) varies significantly with the timing of detection: the earlier the diagnosis, the higher the likelihood of achieving a complete cure (or at least a better outcome). Ogmen et al. show that the routine measurement of calcitonin in serum could lead to an earlier MTC diagnosis.
-
Droplet digital polymerase chain reaction detection of KRAS mutations in pancreatic FNA samples: Technical and practical aspects for routine clinical implementation Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-03 Yara Mansour, Mehdi Boubaddi, Typhaine Odion, Marion Marty, Geneviève Belleannée, Arthur Berger, Clément Subtil, Christophe Laurent, Sandrine Dabernat, Samuel Amintas
Pancreatic adenocarcinoma (PDAC) is associated with a 5-year survival rate of less than 6%, and current treatments have limited efficacy. The diagnosis of PDAC is mainly based on a cytologic analysis of endoscopic ultrasound–guided fine-needle aspiration (EUS-FNA) samples. However, the collected specimens may prove noncontributory in a significant number of cases, delaying patient management and treatment
-
Cytologic risk stratification of medullary thyroid carcinoma: Does it make the grade? Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-02 Michiya Nishino
Recent efforts to develop a histologic grading system for medullary thyroid carcinoma is gaining broad acceptance. How well do these grading parameters translate to cytology specimens?
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-03
No abstract is available for this article.
-
Heightened but variable COVID-19 risks for patients with cancer Cancer Cytopathol. (IF 3.4) Pub Date : 2024-02-03 Bryn Nelson, William Faquin
Four years into the coronavirus disease 2019 (COVID-19) pandemic, multiple studies have agreed that patients with cancer are more susceptible to COVID-19 infection and have a higher risk of worse outcomes than the general population. Large cohort studies have revealed plenty of nuances, however, while raising additional questions in need of better answers. Some cancer types, such as hematologic malignancies
-
Implementation of The Paris System for Reporting Urine Cytology improves diagnostic accuracy of selective upper urinary tract cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-31 Kosuke Miyai, Misaki Nakayama, Shinya Minabe, Sho Ogata, Keiichi Ito, Susumu Matsukuma
The Paris System for Reporting Urine Cytology (TPS) recommends diagnostic criteria for urinary tract cytology, focusing primarily on the detection of high-grade urothelial carcinoma (HGUC) in the lower urinary tract. The second edition of TPS (TPS 2.0), published in 2022, extends these recommendations to the upper urinary tract (UUT); however, there is a lack of comprehensive data on this subject.
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-01
No abstract is available for this article.
-
Fine-needle aspiration of amyloidoma: A critical analysis Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-04 Nisha S. Ramani, Bhuvaneswari Krishnan
Amyloid, presenting as a mass, is termed amyloidoma. Among the reported cases, fine-needle aspiration (FNA) of amyloid is often misinterpreted as acellular nondiagnostic material.
-
Generic cancer drugs are still in short supply Cancer Cytopathol. (IF 3.4) Pub Date : 2024-01-01 Bryn Nelson, William Faquin
Generic carboplatin and cisplatin are inexpensive and indispensable. The platinum-based, injectable chemotherapeutic drugs have factored prominently in curative regimens and combination therapies that have significantly extended patients’ lives. By rights, they should be the poster children of cost-effective cancer care. Instead, they have become the focal points of a painful drug shortage in the United
-
Challenging the concept of “risk of malignancy” in cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-21 Ilias P. Nikas, Ricella Souza da Silva, Bernardo Sousa-Pinto, Fernando Schmitt
Several standardized systems for nongynecological cytopathology have been published following the successful implementation of The Bethesda System for Reporting Cervical Cytology. Each of these systems comprises a set of reporting categories accompanied by a risk of malignancy. However, in most cases, these risk of malignancy estimates have not been based on high-quality evidence and often may not
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-09
No abstract is available for this article.
-
An uncertain balance: In search of the sweet spot for cancer screening Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-09 Bryn Nelson, William Faquin
After decades of aggressive cancer treatments, multiple studies have forced a reckoning of overtreatment for low-risk prostate, cervical, breast, and other cancers. Some studies of patients with low-risk prostate cancer managed by active surveillance, for example, have reported 10-year prostate cancer-specific survival rates of nearly 100%. A 2015 study, by contrast, found that of roughly 3000 men
-
Grading medullary thyroid carcinoma on fine-needle aspiration cytology specimens with the International Medullary Thyroid Carcinoma Grading System: A cytologic–histologic correlation Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-08 Kartik Viswanathan, D. Blake Behrman, Daniel J. Lubin
Medullary thyroid carcinoma (MTC) is a rare cancer of parafollicular C-cell origin. The International MTC Grading System (IMTCGS) incorporates mitotic activity, the presence of necrosis, and the Ki67 proliferation rate (PR) to classify MTCs as low or high grade. The ability to predict IMTCGS grade in cytology was assessed.
-
Comprehensive evaluation of benign and malignant etiologies of different serous effusions with the International System for Reporting Serous Fluid Cytopathology: A multi-institutional study in Taiwan Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-08 Chun-Han Lu, Chih-Yi Liu, Jie-Yang Jhuang, Chien-Chin Chen
The International System for Reporting Serous Fluid Cytopathology (ISRSFC) was introduced globally in 2019 in response to the absence of a standardized reporting system for serous fluid cytology. This study presents experiences implementing this system across three distinct hospitals in Taiwan.
-
The diagnostic utility of methylthioadenosine phosphorylase immunohistochemistry for pancreatic ductal adenocarcinoma in FNA and small biopsy specimens Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-06 Sanhong Yu, Leona A. Doyle, Jason L. Hornick, Jeffrey K. Mito
Accurate diagnosis of pancreatic lesions by endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or fine-needle biopsy can be challenging. Although surrogate immunohistochemical markers for genetic alterations associated with pancreatic ductal adenocarcinoma (PDAC) have been identified, they have modest sensitivity. Biallelic loss of CDKN2A occurs in up to 46% of PDACs, and methylthioadenosine
-
Efficacy of Cobas HPV testing for predicting grade 2+ cervical intraepithelial neoplasia in a cancer prevention center and a gynecologic oncology clinic: A single-institution experience Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-06 Elizabeth Davaro, Agata A. Tinnirello, Therese B. Bevers, Andrea Milbourne, Roland Bassett, John Stewart, Ming Guo
To evaluate the efficacy of Cobas human papillomavirus (HPV) testing to predict cervical intraepithelial neoplasia of grade 2 or higher (CIN2+), Cobas HPV testing results were correlated with follow-up biopsy in patients from Cancer Prevention Center (CPC) and Gynecologic Oncology Clinic (GOC) of The University of Texas MD Anderson Cancer Center.
-
Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: A major cancer center experience Cancer Cytopathol. (IF 3.4) Pub Date : 2023-12-06 Mohamed Alhamar, Hikmat A. Al-Ahmadie, Rusmir Feratovic, Oscar Lin
Bladder diverticula are herniations of bladder urothelium and mucosa through the muscularis propria. The reported incidence of neoplasia arising in bladder diverticula is widely variable. The authors’ objective was to study the characteristics and sensitivity of urine cytology in these patients with emphasis on primary intradiverticular bladder cancer (IDBC).
-
Correlation of immediate prevalence of cervical precancers and cancers with HPV genotype and age in women with atypical glandular cells cytology: A retrospective analysis of 369 cases Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-20 Xin Zhou, Wanrun Lin, Yiming Qin, Jing Zhang, Xiaofei Zhang, Huijuan Zhang, Wenxin Zheng, Feng Zhou
This study aims to assess the immediate risk of cervical precancers and cancers in women with atypical glandular cells (AGC) cytology, based on high-risk human papillomavirus (hrHPV) genotypes and age.
-
Second edition of the Milan System for Reporting Salivary Gland Cytopathology: Refining the role of salivary gland FNA Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-16 Esther Diana Rossi, Zubair Baloch, Guliz Barkan, Maria Pia Foschini, Daniel Kurtycz, Marc Pusztaszeri, Philippe Vielh, William C. Faquin
The use of standardized reporting systems for non-gynecologic cytopathology has made enormous gains in popularity during the past decade, including for thyroid fine-needle aspiration, urine cytology, serous effusions, pancreas, lymph nodes, lung, and more. In February 2018, the first edition Atlas of the Milan System for Reporting Salivary Gland Cytopathology (MSRSGC) was published. The MSRSGC defines
-
Diagnostic terminology for benign/low-risk tumors on renal cytology Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-10 Andrew A. Renshaw, Martha B. Pitman
Biopsy of benign and low-risk tumors of the kidney can be grouped into three distinct categories with different levels of risk, and the suggested diagnoses of these tumors should be tailored to their respective category.
-
An old friend, a new insight: Calcitonin measurement in serum and aspiration needle washout fluids significantly increases the early and accurate detection of medullary thyroid cancer Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-10 Berna Evranos Ogmen, Nurcan Ince, Aysegul Aksoy Altınboga, Leyla Akdogan, Sefika Burcak Polat, Birgul Genc, Ebru Menekse, Cevdet Aydin, Oya Topaloglu, Reyhan Ersoy, Bekir Cakir
The sensitivity of cytological (CY) evaluation after fine-needle aspiration (FNA) for detecting medullary thyroid carcinoma (MTC) is a subject of controversy. The routine use of serum calcitonin (CT) in patients with thyroid nodules is not universally adopted. The authors conducted CT screening of FNA washout fluid (FNA-CT) to address the diagnostic challenges. The objective was to assess the contributions
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-01
No abstract is available for this article.
-
The unexpected costs of “free” preventive care Cancer Cytopathol. (IF 3.4) Pub Date : 2023-11-01 Bryn Nelson, William Faquin
This news section is written by a medical journalist and offers Cancer Cytopathology readers timely information on events, issues, and personalities of interest to the subspecialty. In this issue, the first of a two-part series on the struggle to balance preventive care costs and benefits. Federal laws have directed insurers to offer free cancer screening, but loopholes and uneven implementation have
-
Erratum to “p53 expression in cytology samples may represent a marker of early-stage cancer” Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-21
This erratum corrects the following: Policardo F, Tralongo P, Arciuolo D, et al. p53 expression in cytology samples may represent a marker of early-stage cancer. Cancer Cytopathol. 2023;131(6):392-401. doi:10.1002/cncy.22694 Please note that the surname of one of the authors, Lina Cardisciani, was misspelled as “Cardasciani.” The authors regret this error.
-
Thank You to Reviewers 2023 Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-18
Cancer Cytopathology’s reputation is determined by the quality of the manuscripts submitted and the expertise, dedication, and promptness of the individuals who critically review the manuscripts. In this issue, we’d like to congratulate and acknowledge our top reviewers for their outstanding peer review efforts from the period spanning from September 1, 2022, through August 31, 2023. These individuals
-
Bridging the gap to the next generation of learners and column leadership. Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-17 Diane Davis Davey,Sara E Monaco
-
Molecular-derived risk of malignancy and the related positive call rate of indeterminate thyroid cytology diagnoses as quality metrics for individual cytopathologists Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-17 N. Paul Ohori, Jacqueline M. Cuda, Sheldon I. Bastacky, Linwah Yip, Esra Karslioglu-French, Elena M. Morariu, Jagdeesh Ullal, Kimberly M. Ramonell, Sally E. Carty, Yuri E. Nikiforov, Karen E. Schoedel, Raja R. Seethala
Indeterminate thyroid cytopathology diagnoses represent differing degrees of risk that are corroborated by follow-up studies. However, traditional cytologic–histologic correlation may overestimate the risk of malignancy (ROM) because only a subset of cases undergo resection. Alternatively, some molecular tests provide probability of malignancy data to calculate the molecular-derived risk of malignancy
-
Unlocking the potential of organoids in cancer treatment and translational research: An application of cytologic techniques Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-16 Mohamed A. Abd El-Salam, Maria J. Troulis, Chong-Xian Pan, Rema A. Rao
Patient-derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three-dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns
-
Fine-needle aspiration biopsy of axillary lymph nodes: A reliable diagnostic tool for breast cancer staging Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-16 Luai Sallout, Mohamed Tashkandi, Amani Moqnas, Hebah AlMajed, Abdulrhman Al-Naeem, Yazeed Alwelaie
Pathologic evaluation of sentinel lymph node biopsy (SLNB) samples is crucial for axillary staging in patients newly diagnosed with breast cancer. Patients with pathologic evidence of nodal metastasis scheduled for upfront surgery typically also undergo axillary lymph node dissection (ALND). Although SLNB is the gold standard method for detecting nodal metastasis, axillary lymph node fine-needle aspiration
-
Validation of targeted next-generation sequencing of cell-free DNA from archival cerebrospinal fluid specimens for the detection of somatic variants in cancer involving the leptomeninges: Cytopathologic and radiographic correlation Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-09 Alexander J. Neil, Ugonma N. Chukwueke, Nicholas Hoover, Sean R. N. Marris, Vanesa Rojas-Rudilla, Danielle K. Manning, Jeffrey K. Mito, Edmund S. Cibas, Lynette M. Sholl
Leptomeningeal metastases occur across multiple solid and lymphoid cancers, and patients typically undergo cytopathologic assessment of cerebrospinal fluid (CSF) in this setting. For patients diagnosed with metastatic cancer, the detection of actionable somatic mutations in CSF can provide clinically valuable information for treatment without the need for additional tissue collection.
-
Urinary IL-6 and IL-8 as predictive markers in bladder urothelial carcinoma: A pilot study Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-09 Christopher J. VandenBussche, Christopher D. Heaney, Max Kates, John J. Hooks, Kelly Baloga, Lori Sokoll, Dorothy Rosenthal, Barbara Detrick
Cytokines are known to be a key a factor in numerous malignancies and to exert an important regulatory role in the tumor microenvironment. Interest has grown in understanding how cytokines modulate the tumor microenvironment and which cytokines may serve as markers of the tumor process; however, a complete picture of the cytokine landscape in bladder cancer remains unclear.
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-03
No abstract is available for this article.
-
Understanding the “zombie cells” that won’t die Cancer Cytopathol. (IF 3.4) Pub Date : 2023-10-03 Bryn Nelson, William Faquin
This news section is written by a medical journalist and offers Cancer Cytopathology readers timely information on events, issues, and personalities of interest to the subspecialty. In this issue, senescence, a defensive crouch for human cells, is emerging as a highly complicated but newly energized front in the battle against cancer because these “zombie” cells’ refuse to die easily, stop dividing
-
Rapid on-site evaluation (ROSE) of image-guided FNA specimens improves subsequent core biopsy adequacy in clinical trial patients: The impact of preanalytical factors and its correlation with survival Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-28 Ashleigh J. Graham, Mahalia T. Robinson, Jessica Kahler, Javad R. Azadi, Zahra Maleki
Sufficient tumor collection has become of utmost importance in therapeutic experimental protocols. Rapid on-site evaluation (ROSE) ensures adequate sampling for quantification of biomarkers, molecular analyses, and other ancillary studies. The objectives of this study were to evaluate the role of ROSE in trial-associated fine-needle aspiration (FNA) and to analyze predictors of adequacy and cumulative
-
HPV persistence after cervical surgical excision of high-grade cervical lesions Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-25 Giorgio Bogani, Francesco Sopracordevole, Andrea Ciavattini, Enrico Vizza, Paolo Vercellini, Fabio Ghezzi, Giovanni Scambia, Violante Di Donato, Andrea Giannini, Francesco Raspagliesi
Human papillomavirus (HPV) is the primary cause of cervical dysplasia and cervical cancer. Attempts are needed to better categorize patients with HPV in order to provide useful information for prognosticating and appropriately tailoring surveillance.
-
Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non–small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-25 John Diks, Zhenya Tang, Mehmet Altan, Sarah Anderson, Hui Chen, Asif Rashid, Richard Kenneth Yang, Mark J. Routbort, Keyur P. Patel, Gokce A. Toruner, L. Jeffrey Medeiros, Guilin Tang, Rajyalakshmi Luthra, Sinchita Roy-Chowdhuri
Genomic profiling is needed to identify actionable alterations in non–small cell lung cancer (NSCLC). Panel-based testing such as next-generation sequencing (NGS) is often preferred to interrogate multiple alterations simultaneously. In this study, we evaluate the utility of an RNA-based NGS assay to detect genomic alterations in NSCLC cytology specimens and compare these results to fluorescence in
-
Risk of malignancy in renal biopsy: A review Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-25 Andrew A. Renshaw, Martha B. Pitman
The risks of malignancy for cytologic categories in renal biopsy specimens differ from the risks in most other sites. There are obvious areas in which cytopathologists can do better at classifying these cases, and the routine use of immunohistochemistry and core-needle biopsy may improve the accuracy of the classification of these specimens.
-
Cytopathologic diagnosis of extragonadal germ cell tumors: A 10-year institutional review Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-25 Daniel L. Geisler, Mason Marshall, Sheldon I. Bastacky, Samer N. Khader
The occurrence of extragonadal germ cell tumors (EGGCTs), either as primary tumors or metastatic disease, is rare. Forms of cytologic sampling, including fluid analysis, fine-needle aspiration, and/or small-core needle biopsy, have been shown to be reliable methods for the diagnosis of germ cell tumors. This study aims to investigate the utility of cytopathologic techniques in the diagnosis of EGGCTs
-
Thyroid FNA cytology: Impact of the COVID-19 pandemic and vaccination in a Brazilian series Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-25 Rodrigo de Andrade Natal, Afonso Resende Bedin, Aline Alencar Giongo, Everton Mesquita Dias, Rafael Bispo Paschoalini, Arthur Henrique Cunha Volpato, André Luís Alves de Melo, Caio de Carvalho Santos, Ana Lídia Jacintho Delgado, Rozany Mucha Dufloth, Fernando Augusto Soares, Gilda da Cunha Santos
The coronavirus disease 2019 pandemic prompted changes in medical practice, with a reduction in cytopathology volumes and a relative increase in the malignancy rate during lockdown and the initial postlockdown period. To date, no study has evaluated the impact of these changes on the volume of rapid on-site evaluation (ROSE) or on the frequency of cases according to The Bethesda System for Reporting
-
Don't SUMP it! Utility of PLAG1 immunocytochemistry in basaloid SUMP subcategory Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-13 Monica Sanchez-Avila, Youley Tjendra, Yiqin Zuo, Roberto Ruiz-Cordero, Monica Garcia-Buitrago, Merce Jorda, Carmen Gomez-Fernandez, Jaylou M. Velez Torres
Basaloid salivary gland neoplasm of uncertain malignant potential (B-SUMP) is an indeterminate diagnostic subcategory, with pleomorphic adenoma (PA) representing the most common benign neoplasm. Pleomorphic adenoma gene 1 (PLAG1) staining is frequently seen in PAs and could aid in distinguishing them from other basaloid neoplasms. The authors evaluated the utility of PLAG1 immunocytochemistry (ICC)
-
The rationale for the development and publication of the World Health Organization reporting systems for cytopathology and a brief overview of the first editions of the lung and pancreaticobiliary systems Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-13 Andrew S. Field, Martha Pitman, Ian A. Cree, Sule Canberk, Lukas Bubendorf, Ravi Mahrotra, Fernando Schmitt
The International Academy of Cytology has joined with the International Agency for Research on Cancer and the World Health Organization (WHO) to develop international systems for reporting the cytopathology of lung, pancreas and biliary tract, lymph nodes, soft tissue, liver, breast, and kidney and adrenal gland. The WHO recently published the reporting systems for lung and pancreaticobiliary cytopathology
-
Development and validation of a decision tree for distinguishing pulmonary adenocarcinomas with mucinous features and metastatic colorectal adenocarcinoma Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-07 Alexander N. Wein, Chieh-Yu Lin, Jon H. Ritter, Cory T. Bernadt
Diagnosis of mucinous carcinomas in the lung on transbronchial biopsy or fine-needle aspiration (FNA) samples can be difficult for the pathologist, because primary and metastatic tumors can have similar morphological, immunohistochemical, and molecular characteristics. Correct diagnosis is key to determine appropriate therapy and to distinguish primary from metastatic disease. This distinction often
-
Issue Information Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-04
No abstract is available for this article.
-
New chances and challenges for preventing HPV-associated throat cancer Cancer Cytopathol. (IF 3.4) Pub Date : 2023-09-04 Bryn Nelson, William Faquin
This news section is written by a medical journalist and offers Cancer Cytopathology readers timely information on events, issues, and personalities of interest to the subspecialty. In this issue, the recent surge of oropharyngeal squamous cell carcinoma has been blamed almost entirely on the human papillomavirus (HPV). Otolaryngologists are now sensing an opening for increasing vaccination rates and
-
Role of EBUS-TBNA/EUS-FNA and mass spectrometry for diagnosis and typing of lymph node amyloidosis: 10-year experience in two tertiary care academic centers Cancer Cytopathol. (IF 3.4) Pub Date : 2023-08-28 Asghar Naqvi, Michael Bonert, Christian Finley, Katarzyna Czarnecka-Kujawa, Kazuhiro Yasufuku, Joerg Schwock, Vathany Kulasingam, Rohan John, Hyang-Mi Ko
The objectives of this study were to investigate the utility of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)/endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for the diagnosis of amyloidosis coupled with the feasibility of mass spectrometry (MS) for amyloid subtyping.
-
Evaluating local thyroid cytopathology practices by molecular quality metrics: A multi-institutional study on 4651 FNAs with a focus on the role of the interventional cytopathologist Cancer Cytopathol. (IF 3.4) Pub Date : 2023-08-28 Mariantonia Nacchio, Raffaele Palladino, Elena Vigliar, Pasquale Pisapia, Maria Salatiello, Umberto Malapelle, Tommaso Porcelli, Cristina Luongo, Francesco Fonderico, Stefania Masone, Domenico Salvatore, Giancarlo Troncone, Claudio Bellevicine
The diagnostic accuracy of thyroid fine-needle aspiration (FNA) can be highly influenced by the technical skills of the operator performing the procedure and by interobserver variability in microscopic interpretation. This is particularly true for the indeterminate categories. Recently, molecular testing has been proposed as an ancillary tool for monitoring the performance of different thyroid cytopathology